Arbutus Biopharma Corp (ABUS)
3.35
-0.06
(-1.76%)
USD |
NASDAQ |
Jan 08, 16:00
3.345
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma SG&A Expense (Quarterly): 4.537M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 253.50M |
Amicus Therapeutics Inc | 75.11M |
Ionis Pharmaceuticals Inc | 61.60M |
GlycoMimetics Inc | 4.006M |
FibroGen Inc | 17.55M |